False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake

被引：0
作者：
Philipp E. Hartrampf
Anna Katharina Seitz
Markus Krebs
Andreas K. Buck
Constantin Lapa
机构：
[1] University Hospital Würzburg,Department of Nuclear Medicine
[2] University Hospital Würzburg,Department of Urology and Paediatric Urology
[3] University Hospital Würzburg,Comprehensive Cancer Center Mainfranken
[4] University Hospital Augsburg,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2020年 / 47卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2044 / 2046
页数：2
相关论文
共 18 条
[1]  
Hofman MS(2018)[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Lancet Oncol 19 825-833
[2]  
Violet J(2017)F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients Eur J Nucl Med Mol Imaging 44 678-688
[3]  
Hicks RJ(2019)Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617 Theranostics. 9 4841-4848
[4]  
Ferdinandus J(undefined)undefined undefined undefined undefined-undefined
[5]  
Thang SP(undefined)undefined undefined undefined undefined-undefined
[6]  
Akhurst T(undefined)undefined undefined undefined undefined-undefined
[7]  
Giesel FL(undefined)undefined undefined undefined undefined-undefined
[8]  
Hadaschik B(undefined)undefined undefined undefined undefined-undefined
[9]  
Cardinale J(undefined)undefined undefined undefined undefined-undefined
[10]  
Radtke J(undefined)undefined undefined undefined undefined-undefined
12